The report examines the merger and acquisition behavior of private, venture capital-backed biotech and medical device companies.
Based on an analysis of private merger or acquisition transactions of U.S. venture-capital backed companies since 2005, SVB found a continuous rebound in "Big Exits" among life science companies. Big Exits are defined as acquisitions where the upfront payment totaled in excess of $50 million for device companies and $75 million for biotech companies:
• 35 Big Exits in 2011: seven-year high
• $12.5 billion invested in life science: seven-year high
• Increased upfront deal values
• Indications receiving the largest investments since 2005
• Biotech: Oncology, CNS, Anti-Infectives
• Device: Diagnostics, Orthopedics, Cardiovascular
• Sectors with the highest multiples, versus dollars deployed since 2005
• Biotech: Respiratory, Cardiovascular, Oncology
• Device: Surgical, Vascular, Tools
This tandem report looks at emerging trends in life science investments.
Note: In addition to the full report, we've included a presentation with charts and data that are available for your use below.